entertainment -WSS

entertainment

author：entertainment 2025-09-06 02:13:18 - browse：36399

What makes a blockbuster? Can biotech learn from Aduhelm? And how do you replace a singular regulator?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. We explain the debate over Vertex Pharmaceuticals’ novel pain drug, whose success in clinical trials comes with a sizable caveat. We also talk about the latest news in the life sciences, including an epitaph for Aduhelm and the retirement of an FDA icon.

For more on what we cover, here’s the news on Vertex; here’s more on Aduhelm; here’s the exit interview with Janet Woodcock; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： How to fix cancer clinical trials' diversity problem

hotspot

WSS

'Make People Better': The CRISPR babies story you probably don't know

WHO may add ‘noma' to its list of neglected tropical diseases

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

Illumina names Agilent executive as new CEO

A rare thyroid diagnosis led to unexpected, all

Medtronic CEO on promising devices for diabetes, hypertension

entertainment

entertainment

hotspot

Dobbs anniversary: the lost opportunity of abortion as health care

Humana sues Biden admin over Medicare Advantage audit rule

Trump demands the U.S. pay no more for drugs than other countries … again

Advances in CAR

BioMarin wins approval for gene therapy to treat hemophilia A

The FDA weighs the risks of candy

Drug repurposing or repositioning? The language matters

The 10 drugs up first for Medicare price negotiation

Wildfire smoke exposes gaps in outdoor worker protections

Illumina names Agilent executive as new CEO

focus

Advances in CAR

WHO may add ‘noma' to its list of neglected tropical diseases

Eli Lilly to pay $200M for Beam’s stake in gene

House transparency, PBM reform bill gains bipartisan support

Traditional Chinese medicine benefits explored in new JAMA study

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

hotspot

Wikipedia

hotspot

focus